510(k) device
Mammaprint Ffpe
Agendia · Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI, Class II) · First FDA decision Jan 23, 2015, newest Jan 23, 2015Breast cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
0
Naming "Mammaprint Ffpe"
MAUDE reports
0
Brand "Mammaprint Ffpe", since 2015
PubMed studies
1
Mentioning "Mammaprint Ffpe"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Mammaprint Ffpe
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- MAMMAPRINT FFPE510(k)
K141142 · Decided Jan 23, 2015 · 266 days after receipt
Device type: Classifier, Prognostic, Recurrence Risk Assessment, Rna Gene Expression, Breast Cancer (NYI) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38586CGS Administrators, LLCUpdated May 11, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38684WPS Insurance CorporationUpdated Apr 10, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38647Noridian Healthcare Solutions, LLCUpdated Apr 7, 2026
- MolDX: Prognostic and Predictive Molecular Classifiers for Bladder CancerLocal determinationIn effectL38576Palmetto GBAUpdated Apr 7, 2026
- MolDX: EndoPredict Breast Cancer Gene Expression TestLocal determinationIn effectL37356CGS Administrators, LLCUpdated Apr 6, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37913WPS Insurance CorporationUpdated Feb 20, 2026
- MolDX: Breast Cancer Index® (BCI) Gene Expression TestLocal determinationIn effectL37822Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
- MolDX: EndoPredict® Breast Cancer Gene Expression TestLocal determinationIn effectL37295Noridian Healthcare Solutions, LLCUpdated Jan 12, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Mammaprint Ffpe", any status and sponsor, newest update first.
No registered device study names "Mammaprint Ffpe".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Mammaprint Ffpe", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NYI
1 reports: 0 malfunction, 1 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Mammaprint Ffpe"[tiab]. The summary above synthesizes these.
- MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue.
Sapino A, Roepman P, Linn SC, et al. · J Mol Diagn · 2014Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code NYI.
- MammaPrintAgendia, Inc. · De Novo 2020
- Prosigna Breast Cancer Prognostic Gene Signature AssayNanostring Technologies, Inc. · 510(k) 2014
- Modification to MammaprintAgendia · 510(k) 2009
- MammaPrint FFPE NGS KitAgendia, Inc. · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.